The damage at one of Pfizer’s largest injectables facilities could lead to gains for a few Indian companies, analysts feel. However, regulatory risks, litigation pay-outs and other challenges will slow growth for domestic firms and Indian units of multinationals like Abbott and Pfizer in FY24, says rating agency ICRA as Q1 results begin coming in

Despite facing adversity in the US and Asian markets, Indian firm Ajanta Pharma was ultimately able to deliver respectable growth across Q3 as its African branded generics business thrived.